Pneumagen appoints James Noble to board of directors

Clinical stage biotech company Pneumagen has announced the appointment of James Noble as non-executive Chairman of its Board of Directors.

Pneumagen is developing Neumifil – a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs).

Noble has over 30 years of industry experience at both public and private biotech and healthcare companies.

He is currently Chairman at Orexo AB, Sutura Therapeutics and Celleron Therapeutics and non-executive director of Lava Therapeutics N.V.

Douglas Thomson, CEO of Pneumagen, said:

“We are very pleased to welcome James to the Board who brings a wealth of strategic, corporate and financial expertise to Pneumagen. James’ considerable experience will be invaluable as we progress our Phase 2 clinical trial with our lead asset, Neumifil.

“We look forward to leveraging James’ global network and deep knowledge of the biotech sector as we continue our commitment to deliver an important new therapy to vulnerable patients at risk from viral RTIs.”

In 2008, Noble founded Adaptimmune –  a Nasdaq-listed T-cell therapy company, where he worked as Chief Executive Officer until 2019 and is currently on the Board.

Before that, he served as Chief Executive Officer of Immunocore, which he also co-founded.

James Noble added:

“I am honoured to take on the role as Chairman of the Board of Directors at Pneumagen, a company that has already delivered highly encouraging early clinical data.

“I look forward to working closely with the company’s impressive team and driving forward the strategy to deliver such a potentially important new product for patients at high-risk of viral-induced exacerbations caused by respiratory viruses.”

Pneumagen was established as a spin-out from the University of St Andrews in 2016.